1 / 1

Studie Aktiv

Blasten-phase. T315I. Ø T315I. allogene SCT. Studie Aktiv. CML. Studie in Vorbereitung. De novo CML. Imatinib-Versagen. Aura 3. CML IV. Ø T315I. allogene SCT. T315I. Aura . AURA-009 Studie. Wyeth SKI-606. Bosutinib. PHA-739358. Wyeth SKI-606 Phase 3. *. Imatinib vs. Bosutinib.

zinna
Télécharger la présentation

Studie Aktiv

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Blasten-phase T315I Ø T315I allogene SCT Studie Aktiv CML Studie in Vorbereitung De novo CML Imatinib-Versagen Aura 3 CML IV Ø T315I allogene SCT T315I Aura AURA-009 Studie Wyeth SKI-606 Bosutinib PHA-739358 Wyeth SKI-606 Phase 3 * Imatinib vs. Bosutinib WyethSKI-606** Bosutinib** AURA-009 Studie * Mutationsanalyse ** if 2nd line treatment was not Bosutinib PHA-739358 Ansprechpartner: Prof. Brümmendorf , M. Hermes (4353) , J. Granzow (7843) Stand 01.11.2008

More Related